ES2144421T3 - Nuevo derivado tetrapeptidico. - Google Patents

Nuevo derivado tetrapeptidico.

Info

Publication number
ES2144421T3
ES2144421T3 ES92916961T ES92916961T ES2144421T3 ES 2144421 T3 ES2144421 T3 ES 2144421T3 ES 92916961 T ES92916961 T ES 92916961T ES 92916961 T ES92916961 T ES 92916961T ES 2144421 T3 ES2144421 T3 ES 2144421T3
Authority
ES
Spain
Prior art keywords
tetrapeptidic
derivative
new
chem
dolastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92916961T
Other languages
English (en)
Inventor
Kyoichi Sakakibara
Masaaki - Sunstage-Ryoku Gondo
Koichi Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Teikoku Hormone Manufacturing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26525532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2144421(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teikoku Hormone Manufacturing Co Ltd filed Critical Teikoku Hormone Manufacturing Co Ltd
Application granted granted Critical
Publication of ES2144421T3 publication Critical patent/ES2144421T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

UN DERIVADO TETRAPEPTIDO REPRESENTADO POR LA FORMULA GENERAL (1) O SU SAL, TENIENDO UNA ACTIVIDAD CITOSTATICA SUPERIOR QUE DOLASTINA 10, SIENDO POR TANTO UTIL COMO MEDICINA ANTITUMORES, DONDE R1, R2, R3 Y R4 PUEDEN SER IGUALES O DIFERENTES UNOS DE OTROS Y CADA UNO REPRESENTA HIDROGENO, ALQUILO INFERIOR O ARALCILO; Y Q REPRESENTA (A) O UN ENLACE DIRECTO O R5 REPRESENTA HIDROGENO, ALQUILO INFERIOR O ARALQUILO, R6 REPRESENTA HIDROXI, ALKOXI INFERIOR, ARALCOXI O Y R9 PUEDEN SER IGUALES O DIFERENTES UNO DE OTRO, Y CADA UNO REPRESENTA HIDROGENO, ALQUILO INFERIOR, FENILO O UN GRUPO HETEROCICLICO DE 4 A 7 MIEMBROS, QUE TIENE UNO O DOS HETEROATOMOS SELECCIONADOS ENTRE S, O Y N, O, ALTERNATIVAMENTE, R8 Y R9 PUEDEN FORMAR JUNTAMENTE, CON EL ATOMO DE NITROGENO AL CUAL ESTAN UNIDOS, UN ANILLO HETEROCICLICO DE 4 A 7 MIEMBROS, EL CUAL PUEDE ADEMAS CONTENER UN HETEROATOMO SELECCIONADO ENTRE S, O Y N, A2 REPRESENTA UN ENLACE DIRECTO O ALQUILENO INFERIOR, Y R7 REPRESENTA CICLOALQUILO, ARILO ORINDOLILO, SIEMPRE QUE SEA EXCLUIDO EL CASO EN QUE AMBOS R1 Y R2 REPRESENTEN ISOPROPILO, R3 REPRESENTA SEC-BUTILO, R4 REPRESENTA METILO Y Q REPRESENTA TIAZOLILO) FENETILO .
ES92916961T 1991-08-09 1992-08-06 Nuevo derivado tetrapeptidico. Expired - Lifetime ES2144421T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22353491 1991-08-09
JP22539191 1991-08-12

Publications (1)

Publication Number Publication Date
ES2144421T3 true ES2144421T3 (es) 2000-06-16

Family

ID=26525532

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98115259T Expired - Lifetime ES2172069T3 (es) 1991-08-09 1992-08-06 Derivado tetrapeptidico.
ES92916961T Expired - Lifetime ES2144421T3 (es) 1991-08-09 1992-08-06 Nuevo derivado tetrapeptidico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES98115259T Expired - Lifetime ES2172069T3 (es) 1991-08-09 1992-08-06 Derivado tetrapeptidico.

Country Status (13)

Country Link
US (2) US6004934A (es)
EP (2) EP0934950B1 (es)
JP (1) JP2618597B2 (es)
KR (2) KR0185440B1 (es)
AT (2) ATE215962T1 (es)
AU (2) AU662551B2 (es)
CA (1) CA2115355C (es)
DE (2) DE69230824T2 (es)
DK (2) DK0934950T3 (es)
ES (2) ES2172069T3 (es)
GR (1) GR3033397T3 (es)
SG (1) SG87056A1 (es)
WO (1) WO1993003054A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136339C (en) * 1992-05-20 2008-02-05 Andreas Haupt Derivatives of dolastatin
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
PL178766B1 (pl) * 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
ATE282630T1 (de) * 1993-10-01 2004-12-15 Teikoku Hormone Mfg Co Ltd Dolastatin-derivate
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE196913T1 (de) * 1995-04-21 2000-10-15 Teikoku Hormone Mfg Co Ltd Neuartige peptidderivate
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1049481B1 (en) * 1997-09-24 2005-04-20 Arizona Board Of Regents Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
AU1730701A (en) * 1999-12-07 2001-06-18 Santen Pharmaceutical Co. Ltd. Rheumatism remedy containing tetrapeptide derivative as active ingredient
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
KR20010079252A (ko) * 2001-06-27 2001-08-22 홍진의 주름형 드럼을 갖는 드럼 필터
DK1428530T3 (da) * 2001-09-20 2008-12-01 Aska Pharm Co Ltd Tetrapeptidderivatkrystaller
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2008519863A (ja) * 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
TWI439286B (zh) 2007-07-16 2014-06-01 Genentech Inc 抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
MY157403A (en) 2008-01-31 2016-06-15 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
NO2842575T3 (es) 2008-03-18 2018-02-24
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
SG11201401452PA (en) 2011-11-17 2014-06-27 Pfizer Cytotoxic peptides and antibody drug conjugates thereof
EP2889287B1 (en) * 2012-09-20 2016-08-31 Celltrion, Inc. Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same
CN105849086B (zh) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
EP3753578A1 (en) 2013-12-17 2020-12-23 Novartis AG Cytotoxic peptides and conjugates thereof
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017019489A1 (en) 2015-07-24 2017-02-02 George Robert Pettit Quinstatin compounds
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
FI3438118T3 (fi) * 2016-03-29 2023-06-15 Toray Industries Peptidijohdannainen ja sen käyttö
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2021084532A1 (en) * 2019-10-28 2021-05-06 Ariel Scientific Innovations Ltd. Dolastatin 10 analog
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides

Also Published As

Publication number Publication date
AU662551B2 (en) 1995-09-07
DK0934950T3 (da) 2002-07-29
DE69232552T2 (de) 2002-10-31
EP0934950B1 (en) 2002-04-10
US6004934A (en) 1999-12-21
CA2115355C (en) 2007-09-11
ATE190983T1 (de) 2000-04-15
KR100202474B1 (en) 1999-06-15
JP2618597B2 (ja) 1997-06-11
DE69232552D1 (de) 2002-05-16
DK0598129T3 (da) 2000-07-03
GR3033397T3 (en) 2000-09-29
ATE215962T1 (de) 2002-04-15
AU673487B2 (en) 1996-11-07
ES2172069T3 (es) 2002-09-16
DE69230824D1 (de) 2000-04-27
AU2415292A (en) 1993-03-02
AU2001095A (en) 1995-07-20
KR0185440B1 (ko) 1999-04-01
EP0598129A1 (en) 1994-05-25
CA2115355A1 (en) 1993-02-18
EP0598129A4 (en) 1995-10-25
DE69230824T2 (de) 2000-07-27
US5654399A (en) 1997-08-05
WO1993003054A1 (en) 1993-02-18
SG87056A1 (en) 2002-03-19
EP0934950A1 (en) 1999-08-11
EP0598129B1 (en) 2000-03-22

Similar Documents

Publication Publication Date Title
ES2144421T3 (es) Nuevo derivado tetrapeptidico.
DE69533277D1 (de) Dc-89 derivat
ES2110749T3 (es) Derivado de azolilamina.
ES2156155T3 (es) Derivado de pirazol.
ES2117264T3 (es) Nuevo compuesto con actividad inhibitoria de la agregacion plaquetaria.
DE69312776T2 (de) Fungizide 3,4-Diaryl-(5H)-Furan-2-Onederivate
ATE190308T1 (de) Epoxycyclohexendionderivat
DE3881862T2 (de) Disaccharidderivate.
FI963568A0 (fi) Peptidijohdannaisia
KR960702307A (ko) 항불안약 (anxiolytic agent)
EP0994111A4 (en) TETRAHYDROFURANNE DERIVATIVES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 598129

Country of ref document: ES